Body Weight and eGFR during Dulaglutide Treatment in Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease (AWARD-7).
Publication Title
Diabetes, obesity & metabolism
Document Type
Article
Publication Date
2-14-2019
Abstract
In patients with T2D and moderate-to-severe CKD, dulaglutide treatment led to body weight (BW) loss and lesser eGFR decline compared to insulin glargine. Since BW may affect muscle mass, creatinine-based eGFR can be altered independent of kidney function. Cystatin C-based eGFR is not affected by muscle mass. The objective of this post-hoc analysis was to evaluate if lesser eGFR decline with dulaglutide was related to BW loss. Baseline characteristics were similar between treatments ([mean±SD] age: 64.6±8.6 years, women: 48%, BW: 89.1±17.7 kg, eGFR [CKD-EPI-cystatin C] 38±14 mL/min/1.73m
Clinical Institute
Kidney & Diabetes
Specialty/Research Institute
Nephrology
Specialty/Research Institute
Endocrinology
COinS
